American Journal of Cardiovascular Drugs

, Volume 10, Issue 4, pp 239–246 | Cite as

Effect of an Olmesartan Medoxomil-Based Treatment Algorithm on Systolic Blood Pressure in Patients with Stage 1 or 2 Hypertension

A Randomized, Double-Blind, Placebo-Controlled Study
  • Dean J. Kereiakes
  • Jen-Fue Maa
  • Ali Shojaee
  • Robert Dubiel
Original Research Article


Background and Objective

Elevated systolic BP (SBP) is a major contributor to cardiovascular disease. SBP control reduces the occurrence of stroke, heart failure, and cardiovascular and total mortality. The aim of this study was to analyze the magnitude of SBP reductions and the achievement of individual SBP targets in the original BENIFORCE study.


An olmesartan medoxomil-based treatment algorithm was evaluated in a double-blind, placebo-controlled titration study in 276 patients with stage 1 (47.1%) or 2 (52.9%) hypertension. After placebo run-in, patients were randomized to placebo (12 weeks) or olmesartan medoxomil 20 mg/day (weeks 1–3). Olmesartan medoxomil was uptitrated to 40 mg/day (weeks 4–6), then olmesartan medoxomil/hydrochlorothiazide (HCTZ) 40/12.5 mg per day (weeks 7–9), and olmesartan medoxomil/HCTZ 40/25 mg per day (weeks 10–12) if BP remained ≥120/80 mmHg at any time interval.


The BENIFORCE study was a multicenter (29 sites) study conducted between January and October 2007 in the US.


In patients receiving olmesartan medoxomil-based therapy, 81.0%, 67.2%, and 46.6% of patients with stage 1 hypertension and 70.4%, 49.4%, and 23.5% of patients with stage 2 hypertension achieved SBP targets of <140, <130, and <120 mmHg, respectively (all p<0.01 vs placebo). The proportions of patients achieving SBP targets increased with escalating doses of olmesartan medoxomil and HCTZ, administered alone or in combination, and was highest for combination therapy. Similarly, escalating doses of olmesartan medoxomil or olmesartan medoxomil/HCTZ increased the proportion of patients achieving SBP reductions of >15 but ≤30, >30 but ≤45, and >45 mmHg compared with placebo.


An olmesartan medoxomil-based treatment algorithm effectively reduced SBP and achieved SBP targets in patients with stage 1 or 2 hypertension. This regimen resulted in >80% of patients achieving SBP reductions of ≥15 mmHg while 44% achieved SBP reductions of >30 mmHg.


  1. 1.
    Ostchega Y, Yoon SS, Hughes J, et al. Hypertension awareness, treatment, and control: continued disparities in adults. United States, 2005–2006. NCHS Data Brief 2008; (3): 1–8.Google Scholar
  2. 2.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics: 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117(4): e25–146.PubMedCrossRefGoogle Scholar
  4. 4.
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Ingelsson E, Gona P, Larson MG, et al. Altered blood pressure progression in the community and its relation to clinical events. Arch Intern Med 2008; 168(13): 1450–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet 2008; 371(9631): 2219–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25(3): 305–13.PubMedCrossRefGoogle Scholar
  8. 8.
    O’Rourke M. Mechanical principles in arterial disease. Hypertension 1995; 26(1): 2–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Yambe M, Tomiyama H, Yamada J, et al. Arterial stiffness and progression to hypertension in Japanese male subjects with high normal blood pressure. J Hypertens 2007; 25(1): 87–93.PubMedCrossRefGoogle Scholar
  10. 10.
    O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46(1): 200–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Alli C, Avanzini F, Bettelli G, et al. The long-term prognostic significance of repeated blood pressure measurements in the elderly: SPAA (Studio sulla Pressione Arteriosa nell’Anziano) 10-year follow-up. Arch Intern Med 1999; 159(11): 1205–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20(8): 1461–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Waeber B, Mourad JJ. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension. Am J Hypertens 2006; 19(9): 985–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Izzo Jr JL, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens 2007; 9(1): 36–44.CrossRefGoogle Scholar
  15. 15.
    Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich) 2008; 10(12): 911–21.CrossRefGoogle Scholar
  16. 16.
    Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103(9): 1245–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Franklin SS, Gustin Wt, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96(1): 308–15.Google Scholar
  18. 18.
    Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374(9689): 525–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010 Apr 29; 362(17): 1575–85.Google Scholar
  20. 20.
    SPRINT. Working group report: Expert panel on a hypertension treatment trial initiative meeting summary, 2007 [online]. Available from URL: http://www.nhlbinihgov/meetings/workshops/hypertsnsion-fullpdf [Accessed 2010 Jul 1].
  21. 21.
    SPRINT. National Institutes of Health: systolic blood pressure intervention trial (SPRINT) clinical center [nline]. Available from URL: [Accessed 2010 Jun 23].
  22. 22.
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50(2): 299–305.PubMedCrossRefGoogle Scholar
  24. 24.
    Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006; 48(5): 846–52.PubMedCrossRefGoogle Scholar
  25. 25.
    Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47(3): 345–51.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Dean J. Kereiakes
    • 1
  • Jen-Fue Maa
    • 2
  • Ali Shojaee
    • 2
  • Robert Dubiel
    • 2
  1. 1.The Christ Hospital Heart and Vascular Center/The Carl and Edyth Lindner Center for Research and EducationThe Christ HospitalCincinnatiUSA
  2. 2.Daiichi Sankyo, Inc.ParsippanyUSA

Personalised recommendations